Filana Therapeutics (FLNA) 获得FDA批准恢复癫痫试验；市场定价反映增长不确定性
· gurufocus.com
2026年9月22日，Filana Therapeutics Inc（纳斯达克：FLNA）获得FDA批准，解除对其主要候选药物simufilam的临床暂停，从而得以
On September 22, 2026, Filana Therapeutics Inc (NASDAQ: FLNA) received FDA clearance to lift the clinical hold on its lead drug candidate simufilam, enabling th...